Neuro-Oncology: Dual Inhibition of MAPK and TORC1 Signaling Retards Development of Radiation Resistance in Pediatric BRAF V600E Glioma Models (Chen, Houghton, et al labs)
April 11, 2025
Abstract Background MAPK pathway inhibitors (MAPKi) have shown significant efficacy in treating childhood BRAF-activated brain tumors. For tumors harboring BRAFV600E mutations, the drugs are rarely curative, and patients can become refractory to treatment. MAPKi, combining X-radiation therapy (XRT), may improve the cure rate, but the development of XRT-resistance is a challenge. Read Full Text
